Category: Industrial members

Antibody drugs are now widely accepted in companion animal health. 272BIO is developing a pipeline of VHH based therapeutic and prophylactic drug to address complex diseases at affordable prices for both developers and customers. The flexibility and modularity of VHH, combined with their suitability to be produced across many different microbial expression systems make them highly suitable for the development of bi- and multi-valent drugs targeting different pathophysiological pathways. 

272BIO is making use of the advantages of VHH to develop innovative second-generation treatments for complex diseases including canine atopic dermatitis, osteoarthritis, oncology etc.

A key goal for 272BIO is to develop VHH antibody drugs to transform the lives of patients by addressing the different drivers of disease to result in superior clinical efficacy and better disease control.  Development costs, modest market sizes and high drug prices represent barriers to entry for animal health companies, prescribers and pet-parents as well. To overcome these hurdles necessitates the use of expression and manufacturing processes suitable for the challenges of animal health

The experienced team of seasoned antibody scientists can also assist start up biotech and animal health companies in designing and driving their discovery and development phases for their products.

AM-Team was founded in 2017 by Dr. Wim Audenaert, Dr. Usman Rehman, and Prof. Ingmar Nopens, all having MSc and PhD degrees in either chemical or environmental engineering. AM-Team is a spinoff company of Ghent University with over a decade of expertise in process modelling and simulations.

Customers from all over the globe rely on their leading-edge simulation services and digital tools. They keep on developing tailored digital solutions to match the needs of their customers in the process industry.

They do this by: 

• Developing new process models and methodologies to maximise customer experience and cater the industry needs
• Sharing their expertise at high-level international events and publishing new findings in peer-reviewed scientific papers, often together with customers
• Investing in new hardware and software to maximise simulation speed and accuracy

Thanks to their large team of dedicated simulation engineers, they can handle large projects in a short timeframe. 

OTHER INDUSTRIAL MEMBERS

Cognizant engineers modern businesses. They help their clients modernize technology, reimagine processes and transform experiences so they can stay ahead in the fast-changing world.

Cognizant uses expertise that’s been proven and tested around the globe to help their customers get ahead of challenges, sense opportunities sooner and outpace change.

They develop game-changing digital solutions in many different fields of expertise:

• Digital Engineering
• Intelligent Process Automation
• Industry & Platform Solutions
• Internet of Things
• Artificial Intelligence
• Cloud
• Data
• Life Sciences
• Healthcare
• Manufacturing
• Technology
• …

OTHER INDUSTRIAL MEMBERS

Elegent, a UGent spin-off company, is a dynamic modelling consultancy firm, dedicated to optimizing pharmaceutical development processes. Within the CESPE consortium, we bring invaluable expertise in data-driven and physics-based pharmaceutical engineering. Their focus is accelerating drug product production of solid oral dosages via continuous direct compression and wet granulation through advanced modelling techniques. With a commitment to sustainability and innovation, Elegent complements the consortium’s mission to revolutionize pharmaceutical manufacturing.

The expertise at Elegent centres on bridging the gap between academic innovations and practical applications in pharmaceutical engineering. Within the CESPE consortium, their specialization is utilizing quantitative data-driven support for drug product development. They excel in custom process modelling, formulation, process development, and process analytical technology (PAT) implementation. By leveraging their extensive knowledge in pharmaceutical technology and data science, they help CESPE and its industrial partners drive sustainable innovation, enabling efficient pharmaceutical care delivery to patients.

Fette Compacting is a world-leading supplier of high-tech process equipment for the pharmaceutical industry.

Headquartered near Hamburg, with Sales & Service offices in all major markets, Fette Compacting designs, builds, sells and services worldwide sophisticated machines for the production of pharmaceutical tablets and capsules. The combination of high speed, high precision and full automation requires the very best engineering skills in the fields of mechanical, electronics, software and process design.

Fette Compacting Belgium, located in Mechelen, is the group’s innovation centre for the development and launch of new technologies and machines for faster and more precise pharmaceutical production.

OTHER INDUSTRIAL MEMBERS

The Janssen campus in Belgium (or Janssen Pharmaceutica) is part of the Janssen Pharmaceutical Companies of Johnson & Johnson. A unique fusion of expertise, capabilities and partnerships in R&D, manufacturing and new product launch. Together, they are creating a future where disease is a thing of the past.

As an innovative campus, they focus on important fields of research such as neuroscience, oncology, immunology, infectious diseases, cardiovascular and metabolism and pulmonary hypertension. Fields in which the unmet medical need is high and much is to be done and to achieved.

Janssen in Belgium has been focusing on research and development for more than 60 years. The campus in Belgium has been instrumental in the discovery and development of a new generation of tuberculosis, HIV/AIDS, cancer, infectious diseases and neurological drugs. It was here in Beerse that the first FDA-approved tuberculosis drug in 40 years was discovered and developed.

From early research and development, through supply chain to patient access – their people are making an important contribution to the health of many.

OTHER INDUSTRIAL MEMBERS

At Pfizer, they apply science and their global resources to bring therapies to people that extend and significantly improve their lives. They strive to set the standard for quality, safety, and value in the discovery, development, and manufacture of health care products.

Their global portfolio includes medicines and vaccines as well as many of the world’s best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments, and cures that challenge the most feared diseases of our time.

Consistent with their responsibility as one of the world’s premier innovative biopharmaceutical companies, they collaborate with health care providers, governments, and local communities to support and expand access to reliable, affordable health care around the world.

Their R&D Priorities and Strategy

• Delivering a pipeline of highly differentiated medicines and vaccines where they have a unique opportunity to bring the most important new therapies to patients in need
• Advancing their capabilities that can position them for long-term R&D leadership
• Advancing new models for partnerships with creativity, flexibility and urgency to deliver innovation to patients as quickly as possible.

Pfizer Manufacturing Belgium, the largest production and packaging site of Pfizer worldwide, has now joined the CESPE Innovation cluster. The site has an extensive manufacturing setup with a range of formulation booths, filling lines, automatic inspection lines, packaging lines, freeze driers, and lab facilities. With their clinical pilot plant and experimental plant Pfizer Puurs is also known as a Launch Site within the Global Pfizer network, providing them the ability to quickly scale-up to commercial manufacturing of a new product.

OTHER INDUSTRIAL MEMBERS

RheaVita sells single vial (for R&D), non-GMP multi-vial (for scale-up and stability studies), and full GMP continuous freeze-drying systems.

Next to our engineered solutions we also offer freeze-drying related CDMO services. The freeze-drying of biopharmaceuticals, LNP-based formulations, ATMPs, and other small and large molecules, requires proper formulation and process optimization of the drug substance. Designing the optimal formulation based on the drug substance properties and characteristics is crucial. Furthermore, by applying a model-based strategy, RheaVita provides the opportunity to efficiently design and optimize your freeze-drying process in an extremely fast way with limited product consumption. 

Our manufacturing approach avoids scale-up issues, reduces cycle times, allows fast product development, reduces time-to-patient, lowers production costs, makes use of smaller manufacturing installations, requires less clean room space, provides improved quality assurance thanks to PAT (100% inspection with inherent potential for real-time-release) and leads to improved and uniform product quality and process uniformity.

RheaVita has also set up an academy to share knowledge on freeze-drying where our customers receive a fundamental insight into freeze-drying and analysis of the results and experience the benefits of continuous manufacturing technology.

OTHER INDUSTRIAL MEMBERS

Secoya Technologies is a global provider of services and equipment in particle engineering for the (bio)-pharmaceutical industry. Secoya’s experts have been developing innovative production technologies and equipment by a smart use of micro-structured elements, enabling a faster, precise and secure development and production process.

Their ranges of robust intensified reactors guarantee a stable and reliable production process – at different scale – of high quality (bio-)pharmaceutical products. Their core principle is applied to following technologies and in-house expertise service:

• Crystallization (small molecules, API, excipients…)
• Emulsification / Encapsulation (simple and double emulsion for encapsulation of biomolecules, API…)
• Pervaporation
• Process intensification

The integration of their unique, robust and versatile technologies in their equipment, combined with their unique know-how, allows them to guide their partners with mastering every aspect of the manufacturing process, from laboratory scale to commercial production scale the size of the particles generated and their size distribution as well as to increase the efficiency, productivity and flexibility. Whether it is the development of new products or the improvement of existing products, Secoya’s technologies provide many key benefits:

• Unmatched product quality and secure production
• Implementation of Quality-by-Design
• Reduction of investment cost and risk for the process development
• Reduction of cost of goods sold
• Inherent compatibility with continuous manufacturing
• Manufacturing of new possible molecules

OTHER INDUSTRIAL MEMBERS

Takeda Pharmaceutical Company Limited is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments, guided by their commitment to patients, their people and the planet.

Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetic and Hematology, Neuroscience, and Gastroenterology (GI). They also make targeted R&D investments in Plasma-Derived Therapies and Vaccines.

They are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging their enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline.

Their employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries.

OTHER INDUSTRIAL MEMBERS